Ho-Cheol Kim1, Joon Seon Song2, Jae Cheol Lee3, Dae Ho Lee3, Sang-We Kim3, Jung-Shin Lee3, Woo Sung Kim1, Jin Kyung Rho4, Sun Ye Kim5, Chang-Min Choi6. 1. Department of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine Seoul, South Korea. 2. Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine Seoul, South Korea. 3. Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine Seoul, South Korea. 4. Department of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine Seoul, South Korea ; Asan Institute for Life Sciences, Asan Medical Center, University of Ulsan College of Medicine Seoul, South Korea. 5. Asan Institute for Life Sciences, Asan Medical Center, University of Ulsan College of Medicine Seoul, South Korea. 6. Department of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine Seoul, South Korea ; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine Seoul, South Korea.
Abstract
BACKGROUND: Small cell lung cancer (SCLC) is one of highly aggressive cancers with poor prognosis. Unfortunately, there are as yet no molecular targets that can be exploited to prolong survival in patients with SCLC. This study aimed to investigate possible molecular markers associated with prognosis in limited-stage small cell lung cancer (LS-SCLC). METHODS: The demographic and clinical data for LS-SCLC patients treated in a tertiary care hospital between January 2008 and December 2012 were retrospectively reviewed. NQO1 polymorphism and the expression of p53, SOD2, PARP1 were examined in biopsy specimens, and the factors affecting prognosis were identified. RESULTS: 79 patients with LS-SCLC having available pathologic tissues were analyzed. 84.8% of them received both chemotherapy and radiotherapy. NQO1 polymorphism was detected in 60.0% (45/79; heterozygous in 26 patients, homozygous in 19 patients). Over-expression of p53, SOD2, PARP1 was seen in 45.6% (36/79), 38.0% (30/79) and 41.8% (33/79) of the patients, respectively. The univariate Cox proportional hazards model revealed that serum lactate dehydrogenase (LDH) levels and PARP1 expression were associated with disease progression. In the multivariate analysis, only PARP1 expression was a significant independent prognostic factor for progression-free survival (hazard ratio: 0.494; 95% CI, 0.267-0.913, P = 0.025). CONCLUSIONS: PARP1 expression is correlated with longer progression-free survival in LS-SCLC requiring further studies to clarify the precise role of PARP1 and the relevance of PARP1-targeted therapy.
BACKGROUND:Small cell lung cancer (SCLC) is one of highly aggressive cancers with poor prognosis. Unfortunately, there are as yet no molecular targets that can be exploited to prolong survival in patients with SCLC. This study aimed to investigate possible molecular markers associated with prognosis in limited-stage small cell lung cancer (LS-SCLC). METHODS: The demographic and clinical data for LS-SCLCpatients treated in a tertiary care hospital between January 2008 and December 2012 were retrospectively reviewed. NQO1 polymorphism and the expression of p53, SOD2, PARP1 were examined in biopsy specimens, and the factors affecting prognosis were identified. RESULTS: 79 patients with LS-SCLC having available pathologic tissues were analyzed. 84.8% of them received both chemotherapy and radiotherapy. NQO1 polymorphism was detected in 60.0% (45/79; heterozygous in 26 patients, homozygous in 19 patients). Over-expression of p53, SOD2, PARP1 was seen in 45.6% (36/79), 38.0% (30/79) and 41.8% (33/79) of the patients, respectively. The univariate Cox proportional hazards model revealed that serum lactate dehydrogenase (LDH) levels and PARP1 expression were associated with disease progression. In the multivariate analysis, only PARP1 expression was a significant independent prognostic factor for progression-free survival (hazard ratio: 0.494; 95% CI, 0.267-0.913, P = 0.025). CONCLUSIONS:PARP1 expression is correlated with longer progression-free survival in LS-SCLC requiring further studies to clarify the precise role of PARP1 and the relevance of PARP1-targeted therapy.
Entities:
Keywords:
NQO1 polymorphism; PARP1; Small cell lung cancer; prognosis
Authors: John M Watkins; John A Fortney; Amy E Wahlquist; Keisuke Shirai; Elizabeth Garrett-Mayer; Eric G Aguero; Carol A Sherman; Andrew T Turrisi; Anand K Sharma Journal: Jpn J Radiol Date: 2010-06-30 Impact factor: 2.374
Authors: F Rojo; J García-Parra; S Zazo; I Tusquets; J Ferrer-Lozano; S Menendez; P Eroles; C Chamizo; S Servitja; N Ramírez-Merino; F Lobo; B Bellosillo; J M Corominas; J Yelamos; S Serrano; A Lluch; A Rovira; J Albanell Journal: Ann Oncol Date: 2011-09-09 Impact factor: 32.976
Authors: Jill M Kolesar; Suzanne E Dahlberg; Sharon Marsh; Howard L McLeod; David H Johnson; Steven M Keller; Joan H Schiller Journal: Oncol Rep Date: 2011-04-06 Impact factor: 3.906
Authors: Lauren Averett Byers; Jing Wang; Monique B Nilsson; Junya Fujimoto; Pierre Saintigny; John Yordy; Uma Giri; Michael Peyton; You Hong Fan; Lixia Diao; Fatemeh Masrorpour; Li Shen; Wenbin Liu; Boris Duchemann; Praveen Tumula; Vikas Bhardwaj; James Welsh; Stephanie Weber; Bonnie S Glisson; Neda Kalhor; Ignacio I Wistuba; Luc Girard; Scott M Lippman; Gordon B Mills; Kevin R Coombes; John N Weinstein; John D Minna; John V Heymach Journal: Cancer Discov Date: 2012-09-06 Impact factor: 39.397
Authors: Shivaani Kummar; Alice Chen; Ralph E Parchment; Robert J Kinders; Jay Ji; Joseph E Tomaszewski; James H Doroshow Journal: BMC Med Date: 2012-03-09 Impact factor: 8.775
Authors: Matthew J Schiewer; Amy C Mandigo; Nicolas Gordon; Fangjin Huang; Sanchaika Gaur; Renée de Leeuw; Shuang G Zhao; Joseph Evans; Sumin Han; Theodore Parsons; Ruth Birbe; Peter McCue; Christopher McNair; Saswati N Chand; Ylenia Cendon-Florez; Peter Gallagher; Jennifer J McCann; Neermala Poudel Neupane; Ayesha A Shafi; Emanuela Dylgjeri; Lucas J Brand; Tapio Visakorpi; Ganesh V Raj; Costas D Lallas; Edouard J Trabulsi; Leonard G Gomella; Adam P Dicker; Wm Kevin Kelly; Benjamin E Leiby; Beatrice Knudsen; Felix Y Feng; Karen E Knudsen Journal: EMBO Mol Med Date: 2018-12 Impact factor: 12.137